irinotecan has been researched along with Esophageal Squamous Cell Carcinoma in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 8 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Adenis, A; Al-Rajabi, R; Amonkar, M; Bhagia, P; de la Fouchardiere, C; Girotto, GC; Kulkarni, AS; Mansoor, W; Metges, JP; Norquist, J; Senellart, H; Suryawanshi, S; van Laarhoven, HWM | 1 |
| Bai, C; Bai, Y; Chen, X; Cui, C; Cui, T; Dai, G; Fan, Q; Gao, Q; Gu, K; Huang, Y; Ji, S; Li, W; Li, Y; Liao, W; Liu, Y; Ma, D; Ma, Z; Mancao, C; Peng, B; Shu, Y; Sun, J; Tao, M; Wang, J; Wang, X; Wang, Y; Wu, L; Xiao, J; Xu, J; Xu, N; Yang, L; Yang, Y; Zhang, J; Zhang, T; Zhang, Y; Zhou, H | 1 |
| Chang, J; Hu, Z; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhao, X | 1 |
| Cai, G; Cai, X; Chen, Y; Gong, Y; Ke, S; Qiu, H; Ruan, S; Shi, W; Wu, Y; Zhao, W; Zuo, Z | 1 |
| Bian, W; Chen, S; Dai, X; Tao, L; Wang, J; Wu, W | 1 |
| Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D | 1 |
| Chen, Y; Gubat, JA; Jia, Q; Li, Y; Liu, M; Min, L; Sun, C; Wang, X; Yang, J; Zhang, X; Zhu, C | 1 |
| Adenis, A; Al-Rajabi, R; Bennouna, J; Bhagia, P; Chen, J; de la Fouchardiere, C; Doi, T; Enzinger, P; Ferreira, P; Francois, E; Girotto, G; Hsu, CH; Kang, SP; Kato, K; Kim, SB; Kojima, T; Lee, SH; Lordick, F; Metges, JP; Moriwaki, T; Muro, K; Qin, SK; Senellart, H; Shah, MA; Shen, L; Suryawanshi, S; Wang, R | 1 |
| Chen, Z; Gao, J; Li, S; Li, Y; Lin, X; Lu, Z; Shen, L; Zhang, C; Zou, J | 1 |
| Chen, L; Fu, MY; Tian, D; Wang, Y; Wen, HY; Zhang, KP; Zhang, L; Zhou, Y | 1 |
| Ba, Y; Bai, Y; Cheng, Y; Fan, Q; Feng, J; Hu, C; Huang, J; Li, J; Liu, Y; Lu, P; Ma, C; Wang, X; Wen, L; Wu, L; Xu, B; Yuan, X; Zhang, S | 1 |
| Masuda, U; Matsumoto, A; Minegaki, T; Miyamoto, K; Moriyama, Y; Nishiguchi, K; Ota, K; Tanahashi, M; Tanaka, M; Tsujimoto, M; Wada, A; Yamamoto, A | 1 |
9 trial(s) available for irinotecan and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Disease Progression; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Functional Status; Humans; Immune Checkpoint Inhibitors; Irinotecan; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2022 |
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Immune Checkpoint Inhibitors; Irinotecan; Male; Middle Aged; Paclitaxel; Programmed Cell Death 1 Receptor; Progression-Free Survival; Receptors, Antigen, T-Cell | 2022 |
Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endostatins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Irinotecan | 2022 |
Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Immunotherapy; Irinotecan | 2023 |
Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Irinotecan; Prospective Studies | 2023 |
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progression; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; France; Humans; Irinotecan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Survival Rate; Young Adult | 2020 |
Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Irinotecan; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Prospective Studies; Survival Rate; Treatment Outcome | 2019 |
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Topoisomerase I Inhibitors | 2019 |
3 other study(ies) available for irinotecan and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Thiophenes | 2020 |
A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Topoisomerases, Type I; Esophageal Squamous Cell Carcinoma; Humans; Irinotecan | 2018 |
Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Esophageal Squamous Cell Carcinoma; Histones; Humans; Irinotecan; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2019 |